Abstract
Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.
| Original language | English |
|---|---|
| Pages (from-to) | 208-213 |
| Number of pages | 6 |
| Journal | Neuroendocrinology |
| Volume | 56 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- GH
- GHRH
- Pyridostigmine
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Cellular and Molecular Neuroscience
- Endocrine and Autonomic Systems
Cite this
Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release. / Corsello, Salvatore M.; Tofani, Anna; Casa, Silvia Della; Rota, Carlo A.; Sciuto, Rosa; Colasanti, Simonetta; Barini, Angela; Barbarino, Antonino.
In: Neuroendocrinology, Vol. 56, No. 2, 1992, p. 208-213.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release
AU - Corsello, Salvatore M.
AU - Tofani, Anna
AU - Casa, Silvia Della
AU - Rota, Carlo A.
AU - Sciuto, Rosa
AU - Colasanti, Simonetta
AU - Barini, Angela
AU - Barbarino, Antonino
PY - 1992
Y1 - 1992
N2 - Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.
AB - Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.
KW - GH
KW - GHRH
KW - Pyridostigmine
UR - http://www.scopus.com/inward/record.url?scp=0026665484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026665484&partnerID=8YFLogxK
U2 - 10.1159/000126230
DO - 10.1159/000126230
M3 - Article
C2 - 1407375
AN - SCOPUS:0026665484
VL - 56
SP - 208
EP - 213
JO - Neuroendocrinology
JF - Neuroendocrinology
SN - 0028-3835
IS - 2
ER -